
Jay B. Jones, Ph.D. DABCC



Dr. Jones has served as the Director, Geisinger Regional Laboratories since 1985 and the Director, Ancillary Testing Program for Geisinger Medical Center's Division of Laboratory Medicine since 1992. Concurrently, he has also held the position of Director, Chemistry and Toxicology since 1981.

Process Improvement for Critical and Point of Care Testing (CPOCT): A "Lean" Perspective.


Jay B. Jones, PhD DABCC Director, Regional Labs and Chemistry Geisinger Health System Danville, Pennsylvania



"Lean" for Process Improvement (2 Examples)

- 1) Accessible enterprise POC Prothrombin time (PT-INR) testing to avoid strokes (e.g. "Coag Clinics")
- 2) Highly efficient and integrated enterprise whole blood/blood gas testing to support CV Surgery (e.g. paperless, wireless, OE/RR)

Organized EHR & LIS in the Geisinger Enterprise



- \$80M spent on EHR (EpicCare)
- WAN routers connect to Data
 Center and "Rack & Stack" Virtual
 Client Servers (including SunQuest)
- 28 CS apps from Lab alone



What is "Lean"

- Process efficiency defined and practiced by Toyota, Japan
- Value stream mapping (removing waste)
- Process mapping from test(s) ordering to integrating the test result(s) into practice
- Improving the test process in terms of time, people, materiel, quality, outcome value
- Regarded as a method to cut costs

POCT vs. Core Lab "Lean"

- Patient centric
- Starts when the patient enters the door
- (Pre-, Post-)
 Analytical concurrent
- Single piece flow
- "Real-time" to treatment
- On the spot clinically

- Specimen centric
- Starts when the specimen enters the lab
- (Pre-, Post-)
 Analytical sequenced in "legs"
- Batched
- "Requeing" required for treatment
- Remote clinically

POCT vs. Core Lab "Lean"

- Test acuity is driver to POC (ABGs, PT-INR)
- Specimen prep is driver to Core Lab
- Turnaround time is driver to POC
- Instrument sophistication is driver to Core Lab
- Expense assessed for total cost to treatment may drive to POCT (total process and total value stream mapping)

- 10. POCT consumes less paper and less space storing paper
 - No specimen labels
 - No work lists
 - No requisitions
 - No instrument printouts
 - Etc.

- 9. POCT performed on "fresh" patient specimen without processing of tube(s)
 - No specimen tube (assuming it's the right one)
 - No centrifuge (space, noise, maintenance)
 - Fewer processing artifacts (temperature, changes with transport & storage time)
 - Closer to in vivo

- 8. POCT is mobile and easily deployable
 - Can move with clinical service
 - Can be shared between services & operators
 - Good backup system(s) for multiple locations
 - Can travel with patient (e.g. ECMO)
 - Rapid implementation and training

- 7. POCT is less of a biohazard
 - Specimen contained in test element
 - POCT goes into isolation environment; specimen doesn't come out
 - Less unused specimen to landfill or incinerator
 - No broken tubes or aerosols

- 6. POCT consumes less patient specimen
 - Most of the specimen is wasted in even
 3 mL tubes
 - Blood conservation key in neonates
 - Blood conservation being considered more for all patients

- 5. POCT improves turnaround time (TAT)
 - Focus on problem areas (e.g. ED)
 - Can be used selectively (e.g. trauma cases but not general ED)
 - TAT on POCT device typically the analytical time (no need to account)
 - POCT often only option because of logistics

- 4. POCT is less expensive in many situations
 - Improves patient compliance & hence lessens costly adverse outcomes
 - Saves processing time & resources in lab
 - Look for expensive clinic time savings (e.g OR time)
 - Clinic and patient may enjoy the "bang" for the lab's buck

- 3. POCT less likely to produce a medical error
 - Patient physically scanned (few mis-IDs)
 - Operator physically scanned
 - Few if any handoffs of requests/results
 - Critical results not delayed or lost
 - Medical procedures safeguarded (e.g. creatinine with interventional radiology)

- 2. POCT saves provider time & effort
 - Less queuing up of previous patient encounter
 - Less CRT look up time & distraction
 - Less brain drain to associate lab results to clinical situation
 - More efficient clinical response

- 1. POCT enables integration of testing into clinical flow & clinical judgment
 - "choreography" into clinical process
 - More likely to influence treatment
 - Impact on clinical outcome amplified
 - Immediacy and proximity makes POCT a clinical tool like a stethoscope

Example 1 – Geisinger Health System "Coag Clinics"

- 9000+ Active Patients; 30000+ Total Patients
- 15+ locations staffed by 20 FTE pharmacists;
 CLIA certificates owned by System Lab
- ► ~13,000 Encounters per month
- 1.53 encounters per patient per month
- ▶ 175 250 new patients per month
- > 1% per month growth rate
- 70% of INR's within Therapeutic Range

7-10 Minute Patient "Coag Clinic" Visit

- Patient Registers in lobby("Check in" at Kiosk)
- Pharmacist Sees Appt in EpicCare EHR
- Pharmacist Greets patient in waiting area
- Pharmacist Chats, gets patient history, Finger sticks
- Pharmacist matches patient "story" with PTINR result
- Pharmacist presents card with PTINR result, dose adjustment, next appt schedule to patient
- Any other questions? Bye.

Touch and Swipe Registration Kiosks in Lobbies

http://www.geisinge r.org/locations/const /gw/my_visit/mv_we lcome.html



Touch and Swipe Registration Kiosks in Lobbies

- Typically 4 kiosks clustered in lobby
- Patients prefer kiosk registration rather than waiting in line at a desk
- Pharmacist via EHR screen sees patient is on the way to waiting area and frequently greets them there before they sit down



Regional Anticoagulation Clinics

- 8 CLIA certificates
- Pharmacy does PTINR
- Lab billing/purchasing
- LIS connectivity
- Pharmacy tracks utilization & outcome





"Lean" Tends to be Visual

make sore ton der minn ton notion brestines.

lmg	2mg	2.5mg	3mg	4mg	5mg	6mg	7.5mg	10mg
GUM 40 E	3007 1	3001	Supplied to	SON TIE	307. CF	ENLISON OF	872	

For your protection, tablets are clearly marked with the COUMADIN® (Warfarin Sodium Tablets, USP) Crystalline name and dosage strength to help avoid confusion with your other medications.

*COUMADIN (Warfarin Sodium), the COUMADIN color logo, COLORS OF COUMADIN, and the color and configuration of COUMADIN tablets are trademarks of Bristol-Myers Squibb Company. Any unlicensed use of these trademarks is expressly prohibited under the U.S. Trademark Act.

GHS	WESTERN	REGION ANTICOAGULATION	CLINIC
		APPOINTMENT	

DATE:	TIME:	
	The second second	

TO CHANGE APPOINTMENT CALL (717) 242-4275 MONDAY THRU FRIDAY 8:00 AM - 5:30 PM

COUMADIN DOSE

Sun.	Mon.	TUE.	WED.	THU.	FRI.	SAT.
mg						
tablets						

RESULTS FROM

#A-750-213-F Rev. 11/07js

INR (GOAL

Patients carry out next Appointment, Coumadin Dose, & PT-INR with goal

										GHS W	ESTER	N REGIO	ON ANT	ICOAGU	ULATIO	N CLINI	C
GH	GHS Western Region Anticoagulation Clinic Appointment							APPOINTMENT						100			
Date: Time:						DATE: TIME:											
То	To change appointment call 814-231-6240, MonFri. 8:00am - 4:30pm Toll Free: 1-866-248-1980					m	To Change Appointment Call 814-231-6240, MonFri. 8:00 A.M. – 4:30 P.M. Toll Free 1-866-248-1980						.M.				
				nadin D	ose								WED	DOSE	FRI	SAT	1
	Sun	Mon	Tue	Wed	Thu	Fri	Sat			Sun	Mon	TUE		THU			1
	mg	mg	mg	mg	mg	mg	mg			mg	mg	mg	mg	mg	mg	mg	-
	tablets	tablets		tablets	tablets	tablets	tablets			tablets	tablets	tablets	tablets		tablets	tablets	
		Pro	Results for time (PT)	rom:	seco	nds					RES	ULTS FR	LOM				
INI	R				OAL	-		1			PROT	IME(PT))	S	ECONDS	5	
	80-010-F	Dev. 1/06n	w	,,				,		IN	R		(GC	DAL			
				INTME	NT	ATION (CLINIC			GHS Wes	stern Re	gion An	nticoagu Tin	lation C	linic App	oointme	nt
To Cu	DATE:		CALL 814-	TIME	3:				Т	o change	appointm	ent call 8	14-231-62	240, Mon.	-Fri. 8:00a	m - 4:30p	om
ТОСН	ANGE APP	OINTMENT	TOLL FREE	231-6240, I 1-866-248	MONFRI. -1980	8:00 A.M.	- 4:30 P.N	1				Toll Fre	e: 1-866-	248-1980			
			COUMA										ımadin				
	SUN	Mon	TUE	WED	THU	FRI	SAT			Sun	Mon	Tue	Wed	Thu	Fri	Sat	
	mg	mg	mg	mg	mg	mg	mg			m	g m	g mg	g mg	g mg	mg	mg	
ta	blets	ablets	tablets	tablets	tablets	tablets	tablets			table	tablet			s tablets	tablets	tablets	
		RESUL	TS FROM								Pi	rotime (P7	from: ():	seco	nds		
	P	ROTIM	E(PT)	No.	SEC	CONDS			1	NR				GOAL	-)
	INR)		#	0-480-010-	F Dev. 1/06	nw					
					_	_											
17									-	SHS W	FSTERN	REGIO	N ANTI	COAGU	LATION	CLINI	C
G	HS Wes	tern R	egion An	ticoaqu	lation (linic An	nointm	ont		110	DO I DICI		OINTM				
		Date:	ogion 7 in	Tin	ne:	Jiiiio Ap	pomitin	SIIC .		DATI	F.	500000	Tu	ME.			
То	change :		nent call 8	14-231-62	40, Mon	Fri. 8:00)pm	Т	CHANGE A	APPOINTME	NT CALL 8	14-231-624 REE 1-866-2	0, MONFR	u. 8:00 A.N	1. – 4:30 P	м.
				e: 1-866-2 madin l	PERSONAL PROPERTY.)							MADIN	_			
	Sun	Mon	Tue	Wed		Fri	Sat	1	١	Sun	Mon	TUE	WED	THU	FRI	SAT	
							Sat			mg	mg	mg	mg	mg	mg	mg	
	tablets		g mg							tablets	tablets	tablets	tablets	tablets	tablets	tablets	
	tablets	Lable		from:	tablet	s tablets	tablets	2				7000000	OM				-
		P	rotime (PT								PROTE	ME(DT)	OIVI	S	ECONDS		
IN		San Co. Co.		((GOAL	-)		D. II	PROTI	ME(FI)	(60	S	LCONDS)	
#0-	480-010-F	Dev. 1/06	nw							INI	K		(GC	AL			

Incidence of Adverse Events

Comparison of GHS data with literature

		Reference	Usual Practice	GHS Non-
	GHS Clinics	Anticoagulation	(non-clinic	Clinic Patients
	(1)	Clinics (2)	Patients)*	(3)
Rate of Bleeding	8.67%	15.30%	35.30%	17.10%
Rate of				
Thromboembolic				
Events	1.54%	3.60%	11.80%	20.60%

- (1) Based on 2004-2009 GHS Anticoag data-total of 8847 patients on continous therapy Incidence of Events per patient per year
- (2) Bungard TJ, Gardner L, Archer SL. Evaluation of a pharmacist-managed anticoagulation
- (3) Based on 2009 GHS data total of 307 patients on continous therapy

Drug Therapy Compliance 2003

- "Coag Clinic" patient compliance
 - average compliance with warfarin therapy = 82.3%
 - Comparison <50%
 - 57.5% of patients had compliance rates of 90% or greater
 - Comparison <20%

Stroke Prevention


- 3117 patients were actively managed on anticoagulation therapy during calendar year 2009, with a diagnosis of A-Fib
- For each every 33 A-fib patients on anticoagulation therapy 1 stroke per year is avoided
- 94 potential strokes avoided during 2009

Stroke Prevention

- Cost per Acute Stroke approximately \$12,000 for initial event
 - \$1,128,000 annual cost avoidance
- Ongoing care costs are approximately \$3500 per patient per year
 - \$329,000 per patient per year cost avoidance
- Cost avoidance associated with stroke prevention more than pays for annual cost of the program

Lab's Role in "Coag Clinic"

- Provide/maintain instruments
- QC/PT/CLIA regulatory compliance
- Result reported through LIS to EHR, with billing of outpatient CPT revenue to lab
- Lab highly regarded senior leadership as providing integral patient service at POC
- Pharmacy gets most of the credit and truly values and trusts the lab



ABGs and Whole Blood Chemistries in the CV OR

- Anecdotal "15 minute TAT" from surgeons
- Traditionally tracked In-Lab 2.5 min. TAT
- Observational "lean" process mapping in OR/lab
- ▶ TAT study confirmed 15 min. TAT
- Process improvements designed & prototyped
- Information Technology updates being implemented
- Rolling out process improvements to Enterprise


Lean Process Study "Kaisons"

- 15 min. TAT correct!
- CV OR clerical tasks distracting; need GPS model
- Perfusionists need to stay with pump; POCT distracting
- IT solutions needed (e.g. IGO)
- Tube system inconsistent
- CV OR has enterprise team
- 5 min "Vein to Brain" Aim

Components of Turnaround Time from "Vein to Brain" (V to B)"

A. CV-OR (min:sec) 1) Specimen Collection 2) Test Ordering 3) Results Receipt	Mean 1:48 1:44 3:54	Minimum 0:35 0:53 0:59	Maximum 3:30 3:05 6:23
Total "V to B" TAT	15:23	12:12	22 :16
B. Stat Lab (min:sec)			
1) Specimen Receipt	1:41	0:31	3:41
2) Specimen Testing	0:36	0:20	1:16
3) Result Reporting	1:37	0:45	4:24
Total "In Lab" TAT	2:36	1:19	5:36
C. Pneumatic Tube (min:s	<u>ec)</u>		
1) Derived Transport Time	4:08	1:40	9:55

Efficient, Safe Order Entry



1. Patient Barcode






2. Syringe Barcode



3. Operator Barcode





IVD Industrial Connectivity Consortium (IICC) www.ivdconnectivity.org

- Similar to Connectivity Industrial Consortium (CIC) that created POCT1-A
- Funded by top 7 instrument vendors
- Adopted specifications (i.e. HL7 2.x, IHE, CLSI, etc) for interoperability
- Architecture to include instrument generated orders (IGO) similar to POC instruments (instruments become "smarter")

Conclusion:

- 1) POCT is innately "Lean"
- 2) "Coag Clinics" are a prime example of a "Lean" process improving economic & clinical outcomes
- 3) "Lean" study of enterprise lab support of clinical services will produce improved efficiency (e.g. CV-surgery)
- 4) "Leaning" processes around information systems will continue as a prime lab objective